Refine
Has Fulltext
- yes (37)
Year of publication
- 2021 (37) (remove)
Document Type
- Journal article (33)
- Doctoral Thesis (4)
Language
- English (37) (remove)
Keywords
- Parkinson's disease (5)
- ischemic stroke (4)
- neuroinflammation (3)
- COVID-19 (2)
- cerebellar tDCS (2)
- deep brain stimulation (2)
- immunohistochemistry (2)
- neutrophils (2)
- tMCAO (2)
- thrombo-inflammation (2)
- ADHD (1)
- ALS (1)
- ALS treatment (1)
- Amyotrophic Lateral Sclerosis (ALS) (1)
- Amyotrophic Lateral Sclerosis Assessment Questionnaire 5 (ALSAQ-5) (1)
- BB/OKL rats (1)
- Basal Ganglia (1)
- Basalganglien (1)
- Brain-derived neurotrophic factor (1)
- Cortico-striatal projection neurons (1)
- Crespi effect (1)
- EuroQol Five Dimension Five Level Scale (EQ-5D-5L) (1)
- Fibromyalgia (1)
- Fibromyalgie (1)
- GABAergic neurons (1)
- HMGB1 (1)
- HRUS (1)
- Hornhaut (1)
- IgG (1)
- IntelliCage (1)
- Langerhans cells (1)
- Long COVID (1)
- MIBG scintigraphy (1)
- Medium spiny neurons (1)
- Motor learning (1)
- Motorisches Lernen (1)
- Muster (1)
- NOAC (1)
- Nervenbiopsie (1)
- Nervenultraschall (1)
- Parkinson Krankheit (1)
- Parkinson’s disease (1)
- Plastizität (1)
- Polyneuropathie (1)
- Resilienz (1)
- SARS-CoV (1)
- Sars-CoV-2 (1)
- Sonic hedgehog (1)
- Striatum (1)
- Synaptic plasticity (1)
- T-cells (1)
- T-lymphocytes (1)
- TIND (1)
- Tourette syndrome (1)
- TrkB (1)
- Type 1 diabetes (1)
- Ultraschall (1)
- Western blot (1)
- XAV-939 (1)
- acid sphingomyelinase (1)
- acute ischemic stroke (1)
- albumin (1)
- algorithm (1)
- alpha-7 nicotinic acetylcholine receptor (1)
- alpha‐synuclein (1)
- alpha‐synuclein propagation (1)
- alpha‐synuclein seeding (1)
- amyotrophe Lateralsklerose (1)
- amyotrophic lateral sclerosis (ALS) (1)
- antidepressants (1)
- anxiety (1)
- assistive devices (1)
- attenuation of disease (1)
- balance (1)
- barrier (1)
- basal forebrain cholinergic neurons (1)
- biomarkers (1)
- biopsy (1)
- blood brain barrier (1)
- blood–brain barrier (1)
- cardiac imaging (1)
- caregiver burden (1)
- cerebral ischemia (1)
- cerebrovascular disorders (1)
- choline acetyltransferase (1)
- chronic stimulation (1)
- clinical approach (1)
- closed head injury (1)
- collateral circulation (1)
- comprehension (1)
- computed tomography (1)
- contact-kinin system (1)
- corneal confocal microscopy (1)
- decreasing autonomy (1)
- depression (1)
- diabetic neuropathy (1)
- diagnosis (1)
- diagnostic markers (1)
- directional deep brain stimulation (1)
- dystonia (1)
- echocardiography (1)
- edoxaban (1)
- electrophysiology (1)
- essential tremor (1)
- experimental stroke (1)
- expert opinion (1)
- fibromyalgia sydrome (1)
- finger-tapping task (1)
- functional status (1)
- future directions (1)
- gait (1)
- gene-environment interaction (1)
- gephyrin (1)
- glycine receptor (1)
- glycoprotein receptor Ib (1)
- health-related quality of life (1)
- health-related quality of life (HRQoL) (1)
- hemorrhagic transformation (1)
- hyperekplexia (1)
- image-guided programming (1)
- immunomodulation (1)
- induced pluripotent stem cells (1)
- infantile neuronal ceroid lipofuscinosis (1)
- inflammation (1)
- inflammatory neuropathy (1)
- informal caregiving (1)
- informed consent (1)
- internal medicine (1)
- interview (1)
- iron (1)
- iron dyshomeostasis (1)
- ischemic penumbra (1)
- large vessel occlusion (1)
- leukocytes (1)
- macrophages (1)
- magnetic resonance imaging (1)
- major depression (1)
- mechanical thrombectomy (1)
- medial ganglionic eminence (1)
- mesencephalic locomotor region (1)
- middle cerebral artery occlusion (1)
- mixed methods (1)
- motor learning (1)
- multiple sclerosis (1)
- multiple system atrophy (1)
- nerve biopsy (1)
- nerve tumor (1)
- neurocritical care (1)
- neurodegeneration (1)
- neuroleukemiosis (1)
- neurological (1)
- neurological complications (1)
- neurological examination (1)
- neuropathy (1)
- object recognition memory (1)
- on-site examination (1)
- outcomes (1)
- pain (1)
- pandemic (1)
- pathogenesis (1)
- pathophysiology (1)
- patient triage (1)
- pattern (1)
- peripheral nervous system (1)
- peripheral neuropathy (1)
- photothrombotic stroke (1)
- platelets (1)
- polyneuropathy (1)
- population-based (1)
- preventive treatment (1)
- psychological support (1)
- psychosocial resilience (1)
- purmorphamine (1)
- quality of life (QoL) (1)
- randomized controlled double-blind study (1)
- regulatory T cells (1)
- resilience (1)
- risk of fall (1)
- sciatic nerve (1)
- second hit (1)
- skin biopsy (1)
- skin punch biopsy (1)
- small fiber neuropathy (1)
- small fiber pathology (1)
- socioeconomic status (1)
- somatic resilience (1)
- sphingolipids (1)
- split-belt treadmill (1)
- startle disease (1)
- stress (1)
- stroke (1)
- subthalamic nucleus (1)
- symptom-specific treatment (1)
- target considerations (1)
- task retention (1)
- tetrahydroisoquinoline derivates (1)
- thromboemboli (1)
- thrombosis (1)
- tics (1)
- timing (1)
- transient ischemic attack (1)
- treatment-induced neuropathy in diabetes (TIND) (1)
- tremor (1)
- “bulbar-onset” ALS (bALS) (1)
- “limb-onset” ALS (lALS) (1)
Institute
- Neurologische Klinik und Poliklinik (37) (remove)
EU-Project number / Contract (GA) number
- 825575 (1)
The differentiation of human induced pluripotent stem cells (hiPSCs) into specific cell types for disease modeling and restorative therapies is a key research agenda and offers the possibility to obtain patient-specific cells of interest for a wide range of diseases. Basal forebrain cholinergic neurons (BFCNs) play a particular role in the pathophysiology of Alzheimer’s dementia and isolated dystonias. In this work, various directed differentiation protocols based on monolayer neural induction were tested for their effectiveness in promoting a ventral telencephalic phenotype and generating BFCN. Ventralizing factors [i.e., purmorphamine and Sonic hedgehog (SHH)] were applied at different time points, time intervals, and concentrations. In addition, caudal identity was prevented by the use of a small molecule XAV-939 that inhibits the Wnt-pathway. After patterning, gene expression profiles were analyzed by quantitative PCR (qPCR). Rostro-ventral patterning is most effective when initiated simultaneously with neural induction. The most promising combination of patterning factors was 0.5 μM of purmorphamine and 1 μM of XAV-939, which induces the highest expression of transcription factors specific for the medial ganglionic eminence, the source of GABAergic inter- and cholinergic neurons in the telencephalon. Upon maturation of cells, the immune phenotype, as well as electrophysiological properties were investigated showing the presence of marker proteins specific for BFCN (choline acetyltransferase, ISL1, p75, and NKX2.1) and GABAergic neurons. Moreover, a considerable fraction of measured cells displayed mature electrophysiological properties. Synaptic boutons containing the vesicular acetylcholine transporter (VACHT) could be observed in the vicinity of the cells. This work will help to generate basal forebrain interneurons from hiPSCs, providing a promising platform for modeling neurological diseases, such as Alzheimer’s disease or Dystonia.
Objective: In light of the ongoing COVID-19 pandemic and the associated hospitalization of an overwhelming number of ventilator-dependent patients, medical and/or ethical patient triage paradigms have become essential. While guidelines on the allocation of scarce resources do exist, such work within the subdisciplines of intensive care (e.g., neurocritical care) remains limited.
Methods: A 16-item questionnaire was developed that sought to explore/quantify the expert opinions of German neurointensivists with regard to triage decisions. The anonymous survey was conducted via a web-based platform and in total, 96 members of the Initiative of German Neurointensive Trial Engagement (IGNITE)-study group were contacted via e-mail. The IGNITE consortium consists of an interdisciplinary panel of specialists with expertise in neuro-critical care (i.e., anesthetists, neurologists and neurosurgeons).
Results: Fifty members of the IGNITE consortium responded to the questionnaire; in total the respondents were in charge of more than 500 Neuro ICU beds throughout Germany. Common determinants reported which affected triage decisions included known patient wishes (98%), the state of health before admission (96%), SOFA-score (85%) and patient age (69%). Interestingly, other principles of allocation, such as a treatment of “youngest first” (61%) and members of the healthcare sector (50%) were also noted. While these were the most accepted parameters affecting the triage of patients, a “first-come, first-served” principle appeared to be more accepted than a lottery for the allocation of ICU beds which contradicts much of what has been reported within the literature. The respondents also felt that at least one neurointensivist should serve on any interdisciplinary triage team.
Conclusions: The data gathered in the context of this survey reveal the estimation/perception of triage algorithms among neurointensive care specialists facing COVID-19. Further, it is apparent that German neurointensivists strongly feel that they should be involved in any triage decisions at an institutional level given the unique resources needed to treat patients within the Neuro ICU.
Diabetic polyneuropathy (DPN) is the most common complication in diabetes and can be painful in up to 26% of all diabetic patients. Peripheral nerves are shielded by the blood-nerve barrier (BNB) consisting of the perineurium and endoneurial vessels. So far, there are conflicting results regarding the role and function of the BNB in the pathophysiology of DPN. In this study, we analyzed the spatiotemporal tight junction protein profile, barrier permeability, and vessel-associated macrophages in Wistar rats with streptozotocin-induced DPN. In these rats, mechanical hypersensitivity developed after 2 weeks and loss of motor function after 8 weeks, while the BNB and the blood-DRG barrier were leakier for small, but not for large molecules after 8 weeks only. The blood-spinal cord barrier remained sealed throughout the observation period. No gross changes in tight junction protein or cytokine expression were observed in all barriers to blood. However, expression of Cldn1 mRNA in perineurium was specifically downregulated in conjunction with weaker vessel-associated macrophage shielding of the BNB. Our results underline the role of specific tight junction proteins and BNB breakdown in DPN maintenance and differentiate DPN from traumatic nerve injury. Targeting claudins and sealing the BNB could stabilize pain and prevent further nerve damage.
Dermal and cardiac autonomic fiber involvement in Parkinson's disease and multiple system atrophy
(2021)
Pathological aggregates of alpha-synuclein in peripheral dermal nerve fibers can be detected in patients with idiopathic Parkinson's disease and multiple system atrophy. This study combines skin biopsy staining for p-alpha-synuclein depositions and radionuclide imaging of the heart with [\(^{123}\)I]-metaiodobenzylguanidine to explore peripheral denervation in both diseases. To this purpose, 42 patients with a clinical diagnosis of Parkinson's disease or multiple system atrophy were enrolled. All patients underwent a standardized clinical workup including neurological evaluation, neurography, and blood samples. Skin biopsies were obtained from the distal and proximal leg, back, and neck for immunofluorescence double labeling with anti-p-alpha-synuclein and anti-PGP9.5. All patients underwent myocardial [\(^{123}\)I]-metaiodobenzylguanidine scintigraphy. Dermal p-alpha-synuclein was observed in 47.6% of Parkinson's disease patients and was mainly found in autonomic structures. 81.0% of multiple system atrophy patients had deposits with most of cases in somatosensory fibers. The [\(^{123}\)I]-metaiodobenzylguanidine heart-to-mediastinum ratio was lower in Parkinson's disease than in multiple system atrophy patients (1.94 +/- 0.63 vs. 2.91 +/- 0.96; p < 0.0001). Irrespective of the diagnosis, uptake was lower in patients with than without p-alpha-synuclein in autonomic structures (1.42 +/- 0.51 vs. 2.74 +/- 0.83; p < 0.0001). Rare cases of Parkinson's disease with p-alpha-synuclein in somatosensory fibers and multiple system atrophy patients with deposits in autonomic structures or both fiber types presented with clinically overlapping features. In conclusion, this study suggests that alpha-synuclein contributes to peripheral neurodegeneration and mediates the impairment of cardiac sympathetic neurons in patients with synucleinopathies. Furthermore, it indicates that Parkinson's disease and multiple system atrophy share pathophysiologic mechanisms of peripheral nervous system dysfunction with a clinical overlap.
Tetrahydroisoquinolines (TIQs) such as salsolinol (SAL), norsalsolinol (NSAL) and their methylated derivatives N-methyl-norsalsolinol (NMNSAL) and N-methyl-salsolinol (NMSAL), modulate dopaminergic neurotransmission and metabolism in the central nervous system. Dopaminergic neurotransmission is thought to play an important role in the pathophysiology of chronic tic disorders, such as Tourette syndrome (TS). Therefore, the urinary concentrations of these TIQ derivatives were measured in patients with TS and patients with comorbid attention-deficit/hyperactivity disorder (TS + ADHD) compared with controls. Seventeen patients with TS, 12 with TS and ADHD, and 19 age-matched healthy controls with no medication took part in this study. Free levels of NSAL, NMNSAL, SAL, and NMSAL in urine were measured by a two-phase chromatographic approach. Furthermore, individual TIQ concentrations in TS patients were used in receiver-operating characteristics (ROC) curve analysis to examine the diagnostic value. NSAL concentrations were elevated significantly in TS [434.67 ± 55.4 nmol/l (standard error of mean = S.E.M.), two-way ANOVA, p < 0.0001] and TS + ADHD patients [605.18 ± 170.21 nmol/l (S.E.M.), two-way ANOVA, p < 0.0001] compared with controls [107.02 ± 33.18 nmol/l (S.E.M.), two-way ANOVA, p < 0.0001] and NSAL levels in TS + ADHD patients were elevated significantly in comparison with TS patients (two-way ANOVA, p = 0.017). NSAL demonstrated an AUC of 0.93 ± 0.046 (S.E.M) the highest diagnostic value of all metabolites for the diagnosis of TS. Our results suggest a dopaminergic hyperactivity underlying the pathophysiology of TS and ADHD. In addition, NSAL concentrations in urine may be a potential diagnostic biomarker of TS.
Purpose
Over the course of COVID-19 pandemic, evidence has accumulated that SARS-CoV-2 infections may affect multiple organs and have serious clinical sequelae, but on-site clinical examinations with non-hospitalized samples are rare. We, therefore, aimed to systematically assess the long-term health status of samples of hospitalized and non-hospitalized SARS-CoV-2 infected individuals from three regions in Germany.
Methods
The present paper describes the COVIDOM-study within the population-based cohort platform (POP) which has been established under the auspices of the NAPKON infrastructure (German National Pandemic Cohort Network) of the national Network University Medicine (NUM). Comprehensive health assessments among SARS-CoV-2 infected individuals are conducted at least 6 months after the acute infection at the study sites Kiel, Würzburg and Berlin. Potential participants were identified and contacted via the local public health authorities, irrespective of the severity of the initial infection. A harmonized examination protocol has been implemented, consisting of detailed assessments of medical history, physical examinations, and the collection of multiple biosamples (e.g., serum, plasma, saliva, urine) for future analyses. In addition, patient-reported perception of the impact of local pandemic-related measures and infection on quality-of-life are obtained.
Results
As of July 2021, in total 6813 individuals infected in 2020 have been invited into the COVIDOM-study. Of these, about 36% wished to participate and 1295 have already been examined at least once.
Conclusion
NAPKON-POP COVIDOM-study complements other Long COVID studies assessing the long-term consequences of an infection with SARS-CoV-2 by providing detailed health data of population-based samples, including individuals with various degrees of disease severity.
Trial registration
Registered at the German registry for clinical studies (DRKS00023742).